Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

Inclusion Criteria: * Willing and able to provide written informed consent * Male aged 18 years and above * Histologically or cytologically confirmed adenocarcinoma of the prostate. * Metastatic disease documented by positive bone scan or metastatic lesions other than liver or visceral metastasis on CT, MRI. * Prostate cancer progression to previous castration treatment documented by PSA according to PCWG2 or radiographic progression according to modified RECIST criteria or bone scan progression * Asymptomatic or mildly symptomatic from prostate cancer * Surgically or medically castrated, with testosterone levels of \< 50 ng/dL (\< 2.0 nM). * Previous anti-androgen therapy and progression after withdrawal. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Hemoglobin \>= 10.0 g/dL independent of transfusion * Platelet count \>= 100,000/µL * Serum albumin \>= 3.5 g/dL * Serum creatinine \< 1.5 x ULN or a calculated creatinine clearance \>= 60 mL/min * Serum potassium \>= 3.5 mmol/L * Liver function: a. Serum bilirubin \< 1.5 x ULN (except for patients with documented Gilbert's disease) b. AST or ALT \< 2.5 x ULN * Life expectancy of at least 6 months * Patients who have partners of childbearing potential must be willing to use a method of birth control Exclusion Criteria: * Active infection or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated * Any chronic medical condition requiring a higher dose of corticosteroid than 10mg prednisone/prednisolone daily. * Pathological finding consistent with small cell carcinoma of the prostate * Liver or visceral organ metastasis * Known brain metastasis * Use of opiate analgesics for cancer-related pain, including codeine and dextropropoxyphene, currently or anytime within 4 weeks of Cycle 1 Day 1 * Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC * Radiation therapy for treatment of the primary tumor within 6 weeks of Cycle 1, Day * Radiation or radionuclide therapy for treatment of metastatic CRPC * Previously treated with ketoconazole for prostate cancer for greater than 7 days * Prior systemic treatment with an azole drug (e.g. fluconazole, itraconazole) within 4 weeks of Cycle 1, Day 1 * Prior flutamide (Eulexin) treatment within 4 weeks of Cycle 1, Day 1 * Bicalutamide (Casodex), nilutamide (Nilandron) within 6 weeks of Cycle 1 Day 1 * Uncontrolled hypertension (systolic BP \>= 160 mmHg or diastolic BP \>= 95 mmHg). * Active or symptomatic viral hepatitis or chronic liver disease * History of pituitary or adrenal dysfunction * Clinically significant heart disease * Atrial Fibrillation, or other cardiac arrhythmia requiring therapy * Other malignancy, except non-melanoma skin cancer, with a \>= 30% probability of recurrence within 24 months * Administration of an investigational therapeutic within 30 days of Cycle 1, Day 1 * Any condition which, in the opinion of the investigator, would preclude participation in this trial.